Pathologic and Molecular Characterization of Branch Duct Intraductal Papillary Mucinous Neoplasm With Advanced Neoplasia Under-Recognized by Kyoto High-Risk Stigmata.

Authors

Tassiana Maloof, Wei Chen, Ashwini K Esnakula, Wendy L Frankel, Stacey Culp, Ahmed Abdelbaki, Phil A Hart, Jorge D Machicado, Zobeida Cruz-Monserrate, Zarine K Shah, Timothy M Pawlik, Somashekar G Krishna

Published in

Pancreas. Nov 13, 2026. Epub Nov 13, 2026.

Abstract

Kyoto high-risk stigmata (HRS) guide resection of branch-duct intraductal papillary mucinous neoplasms (BD-IPMNs) but miss a substantial proportion of high-grade dysplasia or invasive carcinoma (HGD/IC). We characterized the pathologic, molecular, and anatomic features of HGD/IC that Kyoto HRS fail to identify, and examined whether they are detectable before surgery by endoscopic ultrasound-guided needle-based confocal laser endomicroscopy (EUS-nCLE) and cyst-fluid molecular analysis.
BD-IPMNs resected from 2015 to 2024 in two prospective trials were retrospectively analyzed. Dysplasia and IPMN-subtype were reassessed by blinded pancreaticobiliary pathologists with consensus and immunohistochemistry. Papillary architecture was classified as macropapillary versus non-macropapillary (micropapillary or flat). Diagnostic performance for HGD/IC was assessed against the consensus pathology reference standard.
Among 68 BD-IPMNs, 26 (38.2%) had HGD/IC, concentrated in non-macropapillary lesions (53.1%, 17/32, vs. 25.0%, 9/36; P=0.017), with the micropapillary pattern carrying the highest proportion (71.4%, 10/14). GNAS mutation was less frequent in non-macropapillary than macropapillary lesions (25.0% vs. 85.2%; P<0.001). Kyoto HRS were highly specific (95.2%) but only 53.8% sensitive; among 52 HRS-negative lesions, 23.1% (12/52) harbored HGD/IC, predominantly non-macropapillary, GNAS-negative, and located in the body or tail. Adding EUS-nCLE raised sensitivity from 52% to 80% (McNemar P=0.016) at 81% specificity, but nCLE was least sensitive in non-macropapillary lesions (43.8%), where absent GNAS provided a complementary preoperative marker.
The HGD/IC missed by Kyoto HRS was characteristically micropapillary, GNAS-negative, and/or in the body or tail. Because architecture and subtype are histopathologic, preoperative recognition rests on combining Kyoto HRS, EUS-nCLE, and cyst-fluid molecular testing. Prospective external validation is warranted.

PMID:
43024803
Bibliographic data and abstract were imported from PubMed on 14 Nov 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.